Introduction
Lynch Syndrome (LS), also known as hereditary nonpolyposis colorectal cancer (HNPCC), is an autosomal dominant genetic condition characterised by a high risk of developing colorectal cancer alongside other forms of cancer, including endometrial, ovarian, stomach, and small intestine cancers.1 LS is caused by mutations in DNA mismatch repair (MMR) genes, which normally function to correct errors that occur during DNA replication. When these genes mutate, errors accumulate, leading to cancer development. Understanding LS is crucial for effective hereditary cancer management.
Muir-Torre Syndrome (MTS) is a rare genetic condition and is considered a variant of LS. It is distinguished by the presence of both sebaceous gland tumours and internal malignancies, particularly those associated with LS.1 First described by Drs. Muir and Torre in the 1960s, this syndrome underscores the connection between dermatological manifestations and internal cancers, highlighting the need for a comprehensive approach to diagnosis and management.
Lynch Syndrome
Genetic mechanisms
LS arises from inherited mutations in DNA MMR genes, primarily MLH1, MSH2, MSH6, and PMS2. These genes play a critical role in maintaining genomic stability by correcting mismatches that occur during DNA replication. When these genes are mutated, the repair process is compromised, leading to microsatellite instability (MSI) and an increased risk of cancer development. MLH1 and MSH2 mutations are the most common, accounting for the majority of LS.2
Clinical manifestations
LS is associated with a wide spectrum of cancers. The most common malignancy is colorectal cancer, with a lifetime risk of up to 80% in affected individuals. Additionally, there is a significantly increased risk of endometrial cancer, with lifetime risks ranging from 30% to 60%. Other associated cancers include ovarian, gastric, small intestine, hepatobiliary, urinary tract, brain, and skin.
The diagnostic criteria for LS include the Amsterdam Criteria and the Revised Bethesda Guidelines. The Amsterdam Criteria focus on family history, requiring at least three relatives with an LS-associated cancer, spanning at least two generations, with one case diagnosed before age 50. The Revised Bethesda Guidelines, on the other hand, consider MSI testing in tumours from patients with colorectal cancer diagnosed before age 50, among other criteria.2
Screening and surveillance
Genetic testing for LS is recommended for individuals meeting the diagnostic criteria or those with a family history suggestive of the syndrome. This testing typically involves sequencing the MMR genes to identify pathogenic mutations.2 For those diagnosed with Lynch Syndrome, regular surveillance is crucial to detect cancers at an early stage. Recommended surveillance protocols include colonoscopy every 1-2 years starting between ages 20-25, or 2-5 years earlier than the youngest age of diagnosis in the family. Women are advised to undergo annual endometrial sampling and transvaginal ultrasound from age 30-35.
Muir-Torre Syndrome
Genetic mechanisms
MTS shares the same genetic basis as LS, with mutations in the MMR genes being responsible for both conditions. MTS is most commonly associated with mutations in the MSH2 gene, although mutations in MLH1 and other MMR genes can also be involved.3 The presence of sebaceous gland tumors in MTS is a key distinguishing feature from LS alone.
Clinical manifestations
MTS is characterised by the presence of sebaceous gland tumours, such as sebaceous adenomas, sebaceous epitheliomas, and sebaceous carcinomas. These tumours often appear on the face, trunk, and extremities. In addition to skin tumours, individuals with MTS have an increased risk of internal malignancies, particularly those associated with LS, such as colorectal and endometrial cancers.
Diagnosis and management
The diagnosis of MTS is based on the presence of sebaceous gland tumours in conjunction with at least one LS-associated internal malignancy. Genetic testing to identify MMR gene mutations can confirm the diagnosis. Management of MTS involves regular dermatological examinations in addition to the cancer surveillance recommended for LS. This integrated approach helps in the early detection and treatment of both skin and internal cancers.3
Relationship between Lynch Syndrome and Muir-Torre Syndrome
Genetic link
The genetic link between LS and MTS lies in the shared MMR gene mutations. Studies have shown that individuals with MTS often have the same mutations as those with LS, particularly in the MSH2 gene. This genetic overlap confirms that MTS is a variant of LS with additional dermatological manifestations.
Clinical implications
Understanding the relationship between LS and MTS has significant clinical implications. Recognising MTS as a variant of LS emphasises the need for comprehensive care that includes both oncological and dermatological evaluation. It also highlights the importance of considering MTS in patients with Lynch Syndrome who develop sebaceous gland tumours, as this can prompt additional cancer surveillance and early intervention.4
Case studies and research
Several case studies have demonstrated the coexistence of LS and MTS in affected families. For instance, a study reported a family with multiple members affected by colorectal cancer, sebaceous gland tumours, and MMR gene mutations, underscoring the genetic and clinical overlap between the two syndromes. These studies provide valuable insights into the natural history and management of MTS in the context of LS.4
Implications for clinical practice
Importance of recognizing Muir-Torre Syndrome in Lynch Syndrome patients
Recognizing MTS in patients with LS is crucial for optimising cancer screening and prevention strategies. The presence of sebaceous gland tumors should prompt dermatological evaluation and a search for internal malignancies. This integrated approach ensures that patients receive comprehensive care that addresses both the cutaneous and internal manifestations of the syndrome.
Genetic counseling and family screening
Genetic counseling is essential for individuals diagnosed with LS or MTS and their families. Family members of affected individuals should be offered genetic testing to determine their risk of carrying MMR gene mutations. Identifying at-risk individuals allows for the implementation of appropriate cancer surveillance and prevention measures. Additionally, genetic counseling provides support and information about the psychological and ethical considerations associated with hereditary cancer syndromes.5
Future directions in research and treatment
Advances in genetic testing
Advances in genetic testing technologies, such as next-generation sequencing, are enhancing our ability to identify pathogenic mutations in LS and MTS. These technologies provide more comprehensive and accurate genetic information, which can improve diagnosis and guide personalised treatment strategies.
Additionally, research into modifier genes and environmental factors may further elucidate the variability in cancer risk and presentation among individuals with these syndromes.
Novel therapies and management strategies
The development of novel therapies and management strategies holds promise for improving outcomes in patients with LS and MTS.5 Targeted therapies, such as immune checkpoint inhibitors, have shown efficacy in treating MMR-deficient tumours, offering new hope for patients with these syndromes. Ongoing research into the molecular mechanisms underlying these conditions will likely lead to the identification of additional therapeutic targets and the development of more effective treatments.
Summary
Lynch Syndrome and Muir-Torre Syndrome are closely related hereditary cancer syndromes characterised by mutations in DNA mismatch repair genes. While LS primarily involves an increased risk of colorectal and other cancers, MTS includes additional dermatological manifestations, such as sebaceous gland tumours. Recognising the relationship between these syndromes is crucial for comprehensive patient care, encompassing both oncological and dermatological evaluation. Advances in genetic testing and targeted therapies hold promise for improving diagnosis and treatment, ultimately enhancing outcomes for individuals affected by these syndromes. Continued research and multidisciplinary collaboration are essential to further our understanding and management of LS and MTS.
References
- Lynch, H. T., & de la Chapelle, A. (2003). Hereditary colorectal cancer. The New England Journal of Medicine, 348(10), 919-932.
- Vasen, H. F. A., Blanco, I., Aktan-Collan, K., Gopie, J. P., Alonso, A., Aretz, S., ... & Møller, P. (2013). Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut, 62(6), 812-823.
- Umar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Ruschoff, J., ... & Srivastava, S. (2004). Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute, 96(4), 261-268.
- Järvinen, H. J., Aarnio, M., Mustonen, H., Aktan-Collan, K., Aaltonen, L. A., Peltomäki, P., ... & Mecklin, J. P. (2000). Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology, 118(5), 829-834.
- South, C. D., Hampel, H., Comeras, I., Westman, J. A., Frankel, W. L., & de la Chapelle, A. (2008). The frequency of Muir-Torre syndrome among Lynch syndrome families. Journal of the National Cancer Institute, 100(4), 277-281.
